IMDX

Insight Molecular Diagnostics Inc.
CAPPED RATING

Insight Molecular Diagnostics Inc. (IMDX) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Growth (D). The rating has held at C- for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.7 / 5.0
Growth
D
Factor Score 1.4 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
D+
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.0
EV / EBITDA -1.8
Rev Growth YoY -53.9%
Gross Margin 48.7%
Price Return 3M -35.6%
Price Return 12M -64.8%
Catalyst Signal 0.00
Market Cap $78.2M
TTM Revenue $1.7M
Price / Sales 46.8
ROE N/A

Historical Factor Score Progression

Held C- for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.7) D (1.4) C (2.3) D+ (1.5) C+ (2.6) C- (2.1)
2026-11-05 C+ (2.7) D (1.4) C (2.3) D (1.4) C+ (2.7) C- (2.1)
2026-10-29 C+ (2.6) D (1.3) C (2.3) D+ (1.8) C+ (2.7) C- (2.1)
2026-10-22 C+ (2.7) D (1.3) C (2.3) C- (2.0) C+ (2.6) C (2.2)
2026-10-15 C+ (2.7) D (1.3) C (2.3) C (2.3) C+ (2.6) C (2.2)
Page 1 of 4